From Wikipedia, the free encyclopedia
Jump to: navigation, search

Heberprot-P is the brand name of a drug developed by scientists at the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba as a cure for diabetic foot ulcer.[1] The product contains epidermal growth factor (EGF) to be applied by intra-lesional injections directly in the wound site.[2][3][4] It has been found to "promote granulation and healing in advanced diabetic foot ulcers".[5] Heberprot-P is indicated for the treatment of poor prognosis of deep, extensive, and terminal DFU not responding to comprehensive and/or extensive conventional methods, particularly in grades 3, 4 and 5 of Wagner's Classification with average ulcer size bigger than 20 cm2,[1] of both neuropathic and ischemic etiology with high risk amputation. Clinical studies in 344 patients with advanced diabetic foot ulcers (Wagner´s grade 3 or 4, median size >20 cm2, ischemic ulcers not excluded) have shown that injected recombinant EGF has the potential to promote complete granulation in more than 80%, with complete wound healing (re-epithelialization) in more than 50% of subjects usually unresponsive to other treatments. Injected recombinant EGF has the potential to reduce amputation rates, with a considerable personal and public health improvement, including longer survival.[1]

Clinical trials and use[edit]

The drug is currently in use in Cuba (since 2007[6]), Argentina, Colombia, Costa Rica, Ecuador,[7] Guatemala, Mexico,[8] Panama,[9][verification needed] Paraguay, Peru, Uruguay, Venezuela,[10] Russia, Turkey[11] and in the Dominican Republic, Kuwait,[12] Vietnam, and the Philippines. Heberprot-P is protected by World patent WO PCT/CU2002/000011.[13] As of July 2012, China has started advanced stage-three tests of the drug, along with colleagues at 100 hospitals throughout the European Union. These trials are the first time Cuban scientists have undertaken advanced clinical trials in developed countries.[14]

The drug has seen successful use in Algeria where at least 700 patients with diabetes could avoid amputation and another 3000 cases of gangrene have been treated. A local firm is manufacturing the drug in Algeria.[15] In South-east Asian countries such as Vietnam and the Philippines, the drug is being used as an advanced wound care healing drug and may be accessed through wound care clinics or wound care specialists among hospitals.[citation needed]

In a retrospective analysis in Argentina it has been shown that, in patients with severe diabetic foot ulcers (Wagner 3 and 4), local administration of Heberprot-P® during a brief period, was effective to induce healing of ulcers in a high percentage of patients. Granulation response was shown in 91% of patients. The complete granulation response rate obtained was 70.3%, with a complete ulcer closure in 69.2% of the patients. Mean wound healing time was 13 weeks.The recurrence rate was low, thus, further amputations were avoided and, as a consequence,patient’s quality of life improved.[16]

Scientists presented the successful results of Heberprot-P in two forums held in the United States: Pan-American Health Organization in Washington, and the meeting at the Conference on the Management of Diabetic Foot Ulcers (DFCON, Los Angeles, 2014).[17]


  1. ^ a b c López-Saura, Pedro A.; Yera-Alos, Isis B.; Valenzuela-Silva, Carmen; González-Díaz, Odalys; del Río-Martín, Amaurys; Berlanga-Acosta, Jorge; Fernández-Montequín, José I.; Acevedo-Castro, Boris; López-Mola, Ernesto; Herrera-Martínez, Luis (2013). "Medical Practice Confirms Clinical Trial Results of the Use of Intralesional Human Recombinant Epidermal Growth Factor in Advanced Diabetic Foot Ulcers" (PDF). Advances in Pharmacoepidemiology & Drug Safety 2 (2). 
  2. ^ "Prescription Information". Center for Genetic Engineering and Biotechnology, Ave. 31 e/ 158 y 190, Cubanacán, Playa La Habana, Cuba. 2010. Retrieved 2012-09-08. 
  3. ^ Berlanga, J.; Fernández, J. I.; López, E.; López, P. A.; del Río, A.; Valenzuela, C.; Baldomero, J.; Muzio, V.; Raíces, M.; Silva, R.; Acevedo, B. E.; Herrera, L. (2013). "Heberprot-P: a novel product for treating advanced diabetic foot ulcer". MEDICC Review 15 (1): 11–15. PMID 23396236. 
  4. ^ "Heberprot-P HD". YouTube. Retrieved 24 November 2014. 
  5. ^ "Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study". International Wound Journal. December 2009. pp. 432–443. doi:10.1111/j.1742-481X.2009.00641.x. Retrieved 2012-09-08. 
  6. ^ Berlanga J, et al. "Heberprot-P: a novel product for treating advanced diabetic foot ul... - PubMed - NCBI". Ncbi.nlm.nih.gov. Retrieved 24 November 2014. 
  7. ^ Ministerio de Salud Pública. "500 pacientes con pie diabético se beneficiarán con el medicamento HEBERPROT-P". Ministerio de Salud Pública. Retrieved 24 November 2014. 
  8. ^ "Hebertprot-P - Pie de Diabetico - Tratamiento". Heberprot-p.com.mx. Retrieved 24 November 2014. 
  9. ^ "Technical File in the Public Health Database" (in Spanish). Comité Técnico Nacional Interinstitucional. Retrieved October 19, 2014. 
  10. ^ "Venezuela: se aplica con éxito tratamiento terapéutico con Heberprot-P". YouTube. Retrieved 24 November 2014. 
  11. ^ "Heberprot-P registered in Turkey". Granma International. September 29, 2014. Retrieved October 19, 2014. 
  12. ^ "The Cuban medicine Heberprot-P will be applied in Kuwait". Cubaheadlines.com. Retrieved 24 November 2014. 
  13. ^ "Patent CA2470971C - Use of pharmaceutical composition containing epidermal growth factor (egf ... - Google Patents". Google.com. Retrieved 24 November 2014. 
  14. ^ "China, Russia to test Cuban diabetes drug". Xinhua English. 2012-07-20. Retrieved 2012-09-09. 
  15. ^ Khris, Badreddine (November 18, 2013). "Traitement du pied diabétique. Heberprot-P, une efficacité avérée !" [Treatment of the diabetic foot. Heberprot-P proven to be effective!]. Liberté (in French). Retrieved October 19, 2014. 
  16. ^ [1][dead link]
  17. ^ "Diabetic Foot Global Conference" (PDF). Dfcon.com. Retrieved 24 November 2014.